Universal testing for thyroid function in pregnant women could reduce miscarriages and negative neurodevelopmental effects for the baby, a University of Birmingham academic will argue in a debate at the European Society of Endocrinology annual meeting today.
The debate ‘Pregnant women should be screened for thyroid hormones and antibodies’ will be held at ECE 2018 in Barcelona
Universal testing for thyroid function in pregnant women could reduce miscarriages and negative neurodevelopmental effects for the baby, a University of Birmingham academic will argue in a debate at the European Society of Endocrinology annual meeting today.
The debate ‘Pregnant women should be screened for thyroid hormones and antibodies’ will be held at ECE 2018 in Barcelona, where two experts take opposing views on whether all pregnant women should be tested for abnormal thyroid function, or if this should only be offered to high risk mothers.
Maternal thyroid function during pregnancy is important for normal growth and development of the child. Abnormalities in thyroid function such as high or low thyroid hormone levels, or autoimmunity against the thyroid gland - are common during pregnancy, and have been associated with poor pregnancy outcomes including increased risk of miscarriage and negative effects on development of the baby’s brain.
Previous studies have investigated how mild thyroid abnormalities affect pregnancy with conflicting results; while some studies have found that thyroid changes are associated with detrimental effects for both child and mother-to-be, others have found no association.
Most medical guidelines do not recommend universal thyroid testing - instead, they advise testing only high risk patients. However, many doctors and patients feel that this targeted approach misses many cases of abnormal thyroid function, and advocate that universal testing is a better strategy.
Dr Kristien Boelaert, of the University of Birmingham’s Institute of Metabolism and Systems Research, UK, proposes universal screening could help detect thyroid problems that are currently missed in up to 75% pregnancies, and stresses that the method could be easily applicable and is a much more cost-effective approach.
She said: “Just as it happens in blood pressure, thyroid function is a continuum and should be monitored to understand what is normal in each case.
“The point at which treatment should be started is unclear, which is why screening programmes should be established.
“Abnormal thyroid function is easily detectable and can be effectively and inexpensively treated.”
On the other side of the debate, Professor Brigitte Velkeniers, from the Vrije Universiteit Brussels, says that evidence for improved pregnancy outcomes following treatment of mild thyroid abnormalities is weak and based on poorly designed studies. Furthermore, ‘normal’ for thyroid hormones is a range, so determining whether levels are high or low will be complex and require monitoring over time.
She said: “Of course, thyroid dysfunction, such as hyper or hypothyroidism, should be diagnosed and treated. Although small changes in thyroid activity have been associated with negative pregnancy outcomes, association does not mean cause.
“Age, BMI, or smoking status of the mother-to-be, may negatively affect the pregnancy, and are also associated with mild thyroid changes. So, using drugs to target these changes in thyroid function may be addressing the wrong problem.
“Additionally, sometimes thyroid autoimmunity can be detected even though the thyroid gland is working normally. When using drugs to treat mild variations in thyroid activity, it remains unclear whether potential benefits outweigh the possible harm.”
More research is needed to establish normal thyroid activity during pregnancy, and both experts agree that the practicalities of universal screening would need further investigation to establish what stages of the pregnancy testing should take place, and who should take responsibility for the screening process.
For more information please contact:
Emma McKinney, Communications Manager (Health Sciences), University of Birmingham, on +44 (0)121 414 6681. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.
Aida de Heras, Communications Executive, European Society of Endocrinology, Tel: (+44) (0)1454 642 206, Mob: (+44) (0)7876824027
